Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-15 (cancelled).

16. (currently amended) A method of treatment of a state comprising preparing an angiogenesis promoting medicament comprising type 1 Placental Growth Factor (PLGF-1) as an active principle, and administering to an individual in need of said medicament to treat the state, wherein the state is selected from the group consisting of:

- diseases and pathological alterations involving the cutaneous or subcutaneous connective tissue,

- scleroderma, and

- early skin aging due to exposures to atmospheric aggressive agents or to protracted solar irradiation and wherein the PLGF-1 is comprised in the medicament in an amount suitable for an administration of 1 to 500 μg per Kg of body per day.

17. (previously presented) The method according to claim 16, wherein the state is selected from the group consisting of localized scleroderma and progressive systemic scleroderma.

18. (previously presented) The method according to claim 17, wherein the localized scleroderma is cutaneous scleroderma and the progressive systemic scleroderma is myocardial scleroderma.

19. (currently amended) The method according to claim 16, wherein the state is a pathological loss of hair due to a ~~particular~~ state selected from the group consisting of alopecia, hormonal disorders, chemotherapy, radiotherapy and administration of medicine.

20. (previously presented) The method according to claim 16, wherein the medicament is in a form suitable for generating a local or systemic effect.

21. (previously presented) The method according to claim 16, wherein the medicament is in a form suitable for endovenous, intramuscular, intrarticular, subcutaneous or topical administration or subcutaneous implant or ionophoresis.

22. (previously presented) The method according to claim 19, wherein the medicament is in a form suitable for endovenous, intramuscular, intrarticular, subcutaneous or topical administration or subcutaneous implant or ionophoresis.

23. (previously presented) A method of cosmetic treatment of a state comprising administering to adult individuals type 1 Placental Growth Factor (PLGF-1) to promote cutaneous or subcutaneous angiogenesis, wherein the state is natural skin aging.

24. (previously presented) A method of cosmetic treatment of a state comprising administering to adult individuals type 1 Placental Growth Factor (PLGF-1) to promote perifollicolar angiogenesis, wherein the state is natural loss of hair.

25. (previously presented) The method according to claim 23, wherein the PLGF-1 is formulated in a cosmetic composition for topical administration.

26. (previously presented) The method according to claim 24, wherein the PLGF-1 is formulated in a cosmetic composition for topical administration.

27. (currently amended) The method according to claim 16, wherein PLGF-1 is comprised in an amount suitable for an administration of 1 ~~to 500 µg per Kg of body per day, preferably of~~ 10 µg/Kg/day to 200 µg/Kg/day.

28. (previously presented) The method according to claim 23, wherein PLGF-1 is comprised in an amount suitable for an administration of 1 to 500 μg per Kg of body per day, preferably of 10 μg/Kg/day to 200 μg/Kg/day.

29. (previously presented) The method according to claim 24, wherein PLGF-1 is comprised in an amount suitable for an administration of 1 to 500 μg per Kg of body per day, preferably of 10 μg/Kg/day to 200 μg/Kg/day.

30. (previously presented) A topical composition comprising type 1 Placental Growth Factor (PLGF-1) as active principle and a pharmaceutically acceptable excipient, wherein at least 98.5% of the PLGF-1 is in active dimeric and multimeric form, at least 70% is in dimeric form and no more than 1.5% is in monomeric form, and wherein PLGF-1 is comprised in an amount from 0.1 mg to 10 mg per gram of said topical composition.

31. (previously presented) A topical composition comprising type 1 Placental Growth Factor (PLGF-1) as active principle and a cosmetically acceptable excipient, wherein at least 98.5% of the PLGF-1 is in active dimeric and multimeric form, at least 70% is in dimeric form and no more than 1.5% is in monomeric form, and wherein PLGF-1 is comprised in an amount from 0.01 mg to 0.09 mg per gram of said topical composition.

32. (previously presented) The composition according to claim 30, in a form selected from the group consisting of a solution, a lotion, a W/O emulsion, an O/W emulsion, a suspension, a liposome suspension, a gel, a cream, a paste, an ointment and a subcutaneous implant.

33. (previously presented) The composition according to claim 31, in a form selected from the group consisting of a solution, a lotion, a W/O emulsion, an O/W emulsion, a suspension, a liposome suspension, a gel, a cream, a paste, an ointment and a subcutaneous implant.

34. (previously presented) The composition according to claim 30, additionally comprising one or more substances capable of stabilizing the PLGF-1 in the active dimeric-multimeric forms.

35. (previously presented) The composition according to claim 31, additionally comprising one or more substances capable of stabilizing the PLGF-1 in the active dimeric-multimeric forms.